Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
321 SEK | +2.23% | -3.31% | -2.58% |
Sales 2024 * | 794M 73.45M | Sales 2025 * | 1.07B 99.41M | Capitalization | 10.11B 935M |
---|---|---|---|---|---|
Net income 2024 * | 70M 6.47M | Net income 2025 * | 158M 14.61M | EV / Sales 2024 * | 12.2 x |
Net cash position 2024 * | 454M 41.95M | Net cash position 2025 * | 476M 44.03M | EV / Sales 2025 * | 8.96 x |
P/E ratio 2024 * |
154
x | P/E ratio 2025 * |
67.2
x | Employees | 160 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 75.13% |
Latest transcript on Xvivo Perfusion AB
1 day | +2.23% | ||
1 week | -3.31% | ||
Current month | +16.73% | ||
1 month | +15.26% | ||
3 months | -0.47% | ||
6 months | +43.95% | ||
Current year | -2.58% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 12-08-31 | |
Director of Finance/CFO | 39 | - | |
Chief Tech/Sci/R&D Officer | 57 | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Camilla Öberg
BRD | Director/Board Member | 60 | 16-04-30 |
Chairman | 65 | - | |
Lars Henrikson
BRD | Director/Board Member | 69 | 19-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 321 | +2.23% | 30,602 |
24-04-22 | 314 | -0.79% | 23,587 |
24-04-19 | 316.5 | -1.40% | 27,963 |
24-04-18 | 321 | -2.13% | 41,987 |
24-04-17 | 328 | +1.08% | 28,621 |
Delayed Quote Nasdaq Stockholm, April 23, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.58% | 906M | |
-2.25% | 186B | |
-1.32% | 107B | |
-3.92% | 67.57B | |
+7.99% | 50.7B | |
+15.74% | 47.2B | |
-0.45% | 39.72B | |
+10.81% | 27.48B | |
+2.34% | 25.65B | |
+13.37% | 24.97B |
- Stock Market
- Equities
- XVIVO Stock